Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Complement C1r-C1s complex is a calcium-dependent tetrameric assembly (C1r2s2) that serves as the catalytic core of the C1 complex in the classical complement pathway (UniProt P00736, P09871). Upon binding of the C1q subcomponent to immune complexes or other activators, the zymogen C1r undergoes autoactivation and subsequently cleaves and activates C1s (Gaboriaud et al., 2014, PMID: 24711612). Activated C1s, a serine protease, then cleaves complement components C4 and C2 to form the C3 convertase, propagating the complement cascade (StatPearls, 2023). Dysregulation or overactivation of this complex is implicated in various autoimmune and inflammatory disorders, such as Cold Agglutinin Disease and Systemic Lupus Erythematosus (PubMed, 32810055). Therapeutic strategies, such as the monoclonal antibody Sutimlimab, focus on inhibiting the enzymatic activity of C1s to prevent downstream complement-mediated hemolysis and tissue damage (FDA, 2022).
Inhibition of the serine protease activity of C1s or C1r to prevent the cleavage of C4 and C2, thereby halting the classical complement cascade (FDA, 2022; StatPearls, 2023).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Complement C1r-C1s complex (C1r-C1s).